Long‐term survival with bevacizumab in heavily pretreated and platinum‐resistant mucinous ovarian cancer: A case report. Issue 2 (9th November 2017)

• Record Type: Journal Article
• Authors: Tarumi, Yosuke; Mori, Taisuke; Matsushima, Hiroshi; Kokabu, Tetsuya; Tsuchiya, Hiroshi; Kitawaki, Jo
• Is Part Of: Journal of obstetrics and gynaecology research. Volume 44:Issue 2(2018)
• Page Start: 347
• Page End: 351
• Publication Date: 2017-11-09
• Subjects: bevacizumab -- long‐term survival -- maintenance -- platinum resistance -- recurrent ovarian cancer; Gynecology -- Periodicals; Obstetrics -- Periodicals; 618.1005
• DOI: 10.1111/jog.13496
• Languages: English
• ISSNs: 1341-8076

Abstract

Abstract: The prognosis of patients with recurrent and platinum‐resistant ovarian cancer is quite poor. Randomized trials have shown that bevacizumab (BEV) can be effective, even in platinum‐resistant ovarian cancer, but only a few such cases of long‐term survival with BEV have been reported. Furthermore, there is no consensus on how many cycles of BEV should be administered. Herein, we report a case of refractory mucinous ovarian cancer showing long‐term survival after six cycles of weekly paclitaxel with BEV followed by 26 cycles of BEV maintenance. Although six prior chemotherapy regimens resulted in progressive disease, the BEV treatment controlled the patient's ascites and improved her performance status. For a further 30 months and 32 cycles of BEV, neither progression of the disease nor severe adverse events have been observed. Our case demonstrates that BEV administration could result in a favorable outcome in heavily pretreated and platinum‐resistant ovarian cancer patients.